← FDA DRUG APPROVALS

FDA NDA · NDA050788

CENTANY

Sponsor: PADAGIS US

APPLICATION
NDA050788
TYPE
NDA
ORIGINAL APPROVAL
2002-12-04
LATEST ACTION
2025-07-10
ROUTE
TOPICAL
DOSAGE FORM
OINTMENT
MARKETING STATUS
Discontinued

Products

CENTANYDiscontinued
MUPIROCIN 2% · OINTMENT · TOPICAL

Approval history

2025-07-10Labeling · Supplement 9 · standard — Letter ↗AP
2015-06-19Labeling · Supplement 5 · standard — Label ↗AP
2014-09-15Manufacturing (CMC) · Supplement 4 · standardAP
2002-12-04Type 3 - New Dosage Form · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →